Insmed Incorporated (NASDAQ:INSM - Get Free Report) insider Martina M.D. Flammer sold 1,384 shares of the company's stock in a transaction that occurred on Tuesday, January 14th. The stock was sold at an average price of $68.72, for a total value of $95,108.48. Following the completion of the sale, the insider now owns 100,165 shares in the company, valued at $6,883,338.80. The trade was a 1.36 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Martina M.D. Flammer also recently made the following trade(s):
- On Friday, January 10th, Martina M.D. Flammer sold 6,172 shares of Insmed stock. The stock was sold at an average price of $63.64, for a total value of $392,786.08.
- On Tuesday, January 7th, Martina M.D. Flammer sold 3,344 shares of Insmed stock. The shares were sold at an average price of $65.91, for a total value of $220,403.04.
Insmed Stock Performance
Shares of INSM traded up $2.55 on Thursday, reaching $72.75. The company's stock had a trading volume of 2,264,024 shares, compared to its average volume of 2,139,833. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $80.53. The stock's 50 day simple moving average is $71.18 and its two-hundred day simple moving average is $72.47. The stock has a market capitalization of $13.01 billion, a P/E ratio of -13.11 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.
Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.19) by ($0.08). The firm had revenue of $93.40 million during the quarter, compared to analysts' expectations of $93.36 million. The firm's revenue for the quarter was up 18.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.10) earnings per share. Research analysts forecast that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Insmed
Hedge funds have recently modified their holdings of the company. Capital CS Group LLC purchased a new position in shares of Insmed in the fourth quarter worth $586,000. Orion Portfolio Solutions LLC increased its holdings in Insmed by 48.5% in the 3rd quarter. Orion Portfolio Solutions LLC now owns 28,087 shares of the biopharmaceutical company's stock valued at $2,050,000 after acquiring an additional 9,170 shares during the last quarter. Ally Bridge Group NY LLC lifted its stake in Insmed by 16.9% in the 3rd quarter. Ally Bridge Group NY LLC now owns 150,833 shares of the biopharmaceutical company's stock worth $11,011,000 after purchasing an additional 21,833 shares in the last quarter. Vestal Point Capital LP boosted its holdings in shares of Insmed by 113.3% during the 3rd quarter. Vestal Point Capital LP now owns 1,600,000 shares of the biopharmaceutical company's stock valued at $116,800,000 after purchasing an additional 850,000 shares during the last quarter. Finally, TimesSquare Capital Management LLC purchased a new position in shares of Insmed during the third quarter valued at about $35,322,000.
Wall Street Analyst Weigh In
Several research analysts have issued reports on INSM shares. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a report on Friday, November 22nd. HC Wainwright reaffirmed a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research report on Friday, November 1st. Truist Financial reissued a "buy" rating and issued a $105.00 target price (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, Bank of America upped their price target on Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, October 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat, Insmed has a consensus rating of "Moderate Buy" and a consensus target price of $83.67.
Check Out Our Latest Report on INSM
About Insmed
(
Get Free Report)
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insmed, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.
While Insmed currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
